Literature DB >> 8960442

Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage.

W Rottbauer1, T Greten, M Müller-Bardorff, A Remppis, J Zehelein, E Grünig, H A Katus.   

Abstract

The diagnosis of acute myocardial infarction is straightforward when anginal pain is accompanied by typical ECG changes and in these patients measurements of cardiac markers are unnecessary in deciding whether thrombolytic therapy is appropriate. Cardiac markers in patients with acute ischaemic coronary syndromes, however, may serve to identify a high risk subgroup of patients with small acute infarctions or minor myocardial damage. In many patients with chest pain a valid diagnosis of myocardial cell injury depends on the result of biochemical assays. In 30% of patients with unstable angina, troponin T is elevated although myocardial infarction was ruled out by cardiac enzymes and ECG recordings. The outcome of these patients at 4 weeks and 6 months follow-up is not different from that of patients with definite myocardial infarction. To guide therapeutic decisions on these patients a troponin T test result needs to be available rapidly. The rapid troponin T test strip assay, which allows the determination of troponin T levels in whole blood at the patient's bedside, can be performed conveniently in the emergency room or in laboratories with less sophisticated equipment and has the potential to aid in the triage of chest pain patients and the selection of therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960442     DOI: 10.1093/eurheartj/17.suppl_f.3

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

Review 1.  Recent advances in the management of unstable angina and non-Q-wave myocardial infarction.

Authors:  R P Steeds; K S Channer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

2.  Long-term mortality of chest pain patients managed according to a decision scheme that aims to avoid inappropriate hospitalisations.

Authors:  A de Torbal; E W M Grijseels; R T van Domburg; J A M Hartman; M L Simoons; E Boersma
Journal:  Neth Heart J       Date:  2003-08       Impact factor: 2.380

3.  Biochemical markers of myocardial injury.

Authors:  P K Nigam
Journal:  Indian J Clin Biochem       Date:  2007-03

4.  miRNA-548c: a specific signature in circulating PBMCs from dilated cardiomyopathy patients.

Authors:  Manveen K Gupta; Carmel Halley; Zhong-Hui Duan; Jason Lappe; Jamie Viterna; Subhra Jana; Katarzyna Augoff; Maradumane L Mohan; Neelakantan T Vasudevan; Jie Na; Khalid Sossey-Alaoui; Xiuping Liu; Chang-Gong Liu; W H Wilson Tang; Sathyamangla V Naga Prasad
Journal:  J Mol Cell Cardiol       Date:  2013-06-02       Impact factor: 5.000

5.  Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention.

Authors:  Jing Yang; Jidong Zhang; Wei Cui; Fan Liu; Ruiqin Xie; Xiaohong Yang; Guoqiang Gu; Hongmei Zheng; Jingchao Lu; Xiuchun Yang; Guangming Zhang; Qian Wang; Xue Geng
Journal:  Anatol J Cardiol       Date:  2014-04-16       Impact factor: 1.596

6.  IFCC Committee on Standardization of Markers of Cardiac Damage: Premises and Project Presentation.

Authors: 
Journal:  EJIFCC       Date:  1999-07-07

7.  Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy.

Authors:  Karolina Weinmann; Jakob Werner; Wolfgang Koenig; Wolfgang Rottbauer; Daniel Walcher; Mirjam Keßler
Journal:  Biomolecules       Date:  2019-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.